Skip to main navigation
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Scholar Rock, Inc. Logo

Scholar Rock, Inc.

  • Careers
  • Newsroom
  • Contact Us
  • Patients & Families
    • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access

    Learn about our commitment to creating possibilities for those living with serious disease.

    Patients & Families

  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors

    Meet Scholar Rock, a biopharmaceutical company committed to improving lives.

    Our Company

  • Our Science
    • Our Science
    • Platform
    • Publications & Posters

    Discover how our breakthrough approach treats complex disease at its biological root.

    Our Science

  • Our Pipeline
    • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
    • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
Link to homepage Investors & Media Financials & Filings

Investors and Media

Financials & Filings

Main content section

Annual Reports

2024 Annual Report
7.07 MB
2023 Annual Report
12.77 MB
2022 Annual Report
3.01 MB
2021 Annual Report
5.25 MB
2020 Annual Report
3.3 MB
2019 Annual Report
4.81 MB
2018 Annual Report
3.22 MB
Filing Date Description Form Filing Group View
May 26, 2021 Report of unscheduled material events or corporate event 8-K
Current Reports
View HTML
0001157523-21-000719.pdf
0001157523-21-000719.rtf
0001157523-21-000719.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 13, 2021 Report of unscheduled material events or corporate event 8-K
Current Reports
View HTML
0001157523-21-000657.pdf
0001157523-21-000657.rtf
0001157523-21-000657.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 13, 2021 Quarterly report which provides a continuing view of a company's financial position 10-Q
Quarterly Filings
View HTML
0001558370-21-007006.pdf
0001558370-21-007006.rtf
0001558370-21-007006.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 13, 2021 Securities offered to employees pursuant to employee benefit plans S-8
Registration Statements
View HTML
0001558370-21-007022.pdf
0001558370-21-007022.rtf
0001558370-21-007022.xls
April 15, 2021 Official notification to shareholders of matters to be brought to a vote ("Proxy") DEF 14A
Proxy Filings
View HTML
0001104659-21-050799.pdf
0001104659-21-050799.rtf
0001104659-21-050799.xls
April 6, 2021 Report of unscheduled material events or corporate event 8-K
Current Reports
View HTML
0001157523-21-000429.pdf
0001157523-21-000429.rtf
0001157523-21-000429.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
March 18, 2021 Report of unscheduled material events or corporate event 8-K
Current Reports
View HTML
0001157523-21-000363.pdf
0001157523-21-000363.rtf
0001157523-21-000363.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
March 18, 2021 Initial filing by director officer or owner of more than ten percent. 3
3,4,5
View HTML
0001179110-21-003593.pdf
0001179110-21-003593.rtf
0001179110-21-003593.xls
March 18, 2021 Statement of changes in beneficial ownership of securities 4
3,4,5
View HTML
0001179110-21-003595.pdf
0001179110-21-003595.rtf
0001179110-21-003595.xls
March 17, 2021 Statement of changes in beneficial ownership of securities 4
3,4,5
View HTML
0001179110-21-003552.pdf
0001179110-21-003552.rtf
0001179110-21-003552.xls
  • First page «
  • Previous page ‹
  • …
  • Page 40
  • Page 41
  • Current page 42
  • Page 43
  • Page 44
  • …
  • Next page ›
  • Last page »

Data provided by Kaleidoscope.

Primary Sidebar

Investor Menu

  • Investors & Media
  • Press Releases
    • Archived Press Releases
  • Events & Presentations
  • Corporate Governance
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
  • Stock Information
    • Historical Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Investor FAQs
  • Contact IR or Media

In this section

Footer

Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
info@scholarrock.com

© 2026 All Rights Reserved
  • Community Guidelines
  • Expanded Access Policy
  • Privacy Policy
  • Terms of Use

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

  • Community Guidelines
  • Expanded Access Policy
  • Privacy Policy
  • Terms of Use
Scholar Rock, Inc. Logo
  • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access
  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors
  • Our Science
    • Our Science
    • Platform
    • Publications & Posters
  • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
    • Immuno-Oncology
      • Cancer (solid tumors)
      • Fibrotic Diseases
    • Hematology
      • Anemia
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Careers
  • Newsroom
  • Contact Us